NCT04337255 · ACTIVE NOT RECRUITING
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
This trial tests whether following the MIND diet for two to three years after a stroke slows cognitive decline compared to standard post-stroke dietary care. Researchers will also look at brain biomarkers tied to Alzheimer's and vascular disease. It enrolls 250 adults aged 55 and older who were hospitalized for an ischemic stroke and discharged home without dementia. This is a Phase NA randomized controlled trial — meaning it tests a behavioral intervention, not a drug.
Eligibility criteria
* Inclusion Criteria * Men and women, 55 years of age - inclusive- or older * Acute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan * Written informed consent by patient prior to study participation * Willingness to complete all assessments and participate in follow-up * Willing to participate and give informed consent * Adequate Visual and auditory acuity to undergo neuropsychological testing * Exclusion criteria * CDR>=0.5 * Nuts, berries, olive oil, or fish allergies * Use of medications to treat Alzheimer's disease or Parkinson's disease * Aphasia * Conditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years * Report of alcohol or substance abuse within six months, or heavy alcohol consumption (>2 drinks/d women; >3 drinks/d men) * Unstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV) * Cancer treatment \<= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion) * Illness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, etc.) * History of liver disease, HIV or Hepatitis C * An intracerebral hemorrhage as documented on CT or MRI * Pre- hospitalization diagnosis of dementia or mild cognitive impairment * Patients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral hemorrhage, intracerebral hemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular hemorrhage * Patients presenting a malignant disease with life expectancy \< 3 years * Residence in a nursing home and thus going back to nursing home upon discharge * Participation in an ongoing investigational drug study * Exception to these guidelines will be rare but may be considered on a case by case basis at the discretion of the PI's
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-21